The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 28, No. 10, pp. 1169-1171.
© 1994 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mallet, L
Right arrow Articles by Mallet, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mallet, L
Right arrow Articles by Mallet, J

Research Articles

Ticlopidine and fatal aplastic anemia in an elderly woman

L Mallet and J Mallet

OBJECTIVE: To report a case of aplastic anemia that developed during ticlopidine treatment. CASE SUMMARY: An 84-year-old woman was started on ticlopidine for secondary stroke prevention. Within six weeks of initiating ticlopidine therapy she developed aplastic anemia. She was hospitalized and received empiric antibiotics, antifungal agents, blood transfusions, platelets, and granulocyte colony-stimulating factor. The patient died on day 76 after beginning ticlopidine. DISCUSSION: Hematologic effects such as neutropenia, thrombocytopenia, agranulocytosis, thrombotic thrombocytopenic purpura, and pancytopenia have been described with the use of ticlopidine. Previous case reports have associated ticlopidine with the development of aplastic anemia. CONCLUSIONS: Ticlopidine can produce fatal hematologic adverse effects, and its use should be reserved as second-line therapy.


This article has been cited by other articles:


Home page
 J Gerontol A Biol Sci Med SciHome page
W. S. Aronow
Use of Antiplatelet Drugs in Secondary Prevention in Older Persons With Atherothrombotic Disease
J Gerontol A Biol Sci Med Sci, May 1, 2007; 62(5): 518 - 524.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
M. E. Ertorer, A. Gokcel, L. Savas, and R. Kocak
Ticlopidine-Induced Marrow Aplasia Treated with Cyclosporine
Clinical and Applied Thrombosis/Hemostasis, April 1, 2002; 8(2): 183 - 185.
[Abstract] [PDF]

Home page
 CMAJHome page
F. L. Paradiso-Hardy, C. M. Angelo, K. L. Lanctot, and E. A. Cohen
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality
Can. Med. Assoc. J., November 1, 2000; 163(11): 1441 - 1448.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
F. Ferrer, J. M. Moraleda, V. Vicente, F. W. LoGerfo, V. R. Wohl, E. Hecht, K. Shaughnessy, M. B. Leon, G. Dangas, R. Erbel, et al.
Antithrombotic Therapy after Coronary-Artery Stenting
N. Engl. J. Med., April 29, 1999; 340(17): 1365 - 1368.
[Full Text]

Home page
 J Neuropsychiatry Clin NeurosciHome page
J. Finsterer
Severe Normochrome and Normocytic Anemia After 19 Months on Ticlopidine
J Neuropsychiatry Clin Neurosci, February 1, 1999; 11(1): 118 - 119.
[Full Text]


homecopy help contact us subscription past issues search current issue
Copyright © 1994 by Harvey Whitney Books Company.